Pharminent · Daily Brief
September 23, 2026
Clinical Data
Amgen’s dazodalibep meets goals in phase 3 Sjögren’s trial
Amgen said its anti-CD40L fusion protein dazodalibep produced statistically significant and clinically meaningful preliminary results in the first of two phase 3 trials in Sjögren’s disease. The drug came to Amgen through its acquisition of Horizon Therapeutics.
BioPharma Dive →$AMGN
Roche reports phase 3 win for sefaxersen in kidney disease
Roche reported a positive phase 3 result for sefaxersen, an Ionis-partnered candidate, in kidney disease. The company said it will discuss the path to approval with regulators.
Fierce Biotech →$RHHBY$IONS
Viking shares rise on updated obesity drug dosing data
Viking Therapeutics reported that trial participants largely maintained their weight loss after switching from a weekly injection to less frequent dosing, and the company’s shares rose.
BioPharma Dive →$VKTX
One-time cell infusion cut osteoporosis fractures 94% in small trial
A one-time infusion of sugar-tagged bone marrow cells reduced fragility fractures by 94% in a small osteoporosis trial in women.
Forbes →
Deals & Partnerships
Novartis licenses BoomRay’s preclinical radioligand therapy in $900M deal
Novartis and BoomRay Pharmaceuticals signed an exclusive worldwide license agreement covering an undisclosed preclinical radioligand therapy asset, in a deal worth up to $900 million.
Pharmaceutical Technology →$NVS
Boehringer and Envisagenics sign $1B cancer target collaboration
Boehringer Ingelheim and Envisagenics entered a research collaboration and option agreement, worth up to $1 billion, to validate tumor-specific targets for precision therapies in solid tumors.
Pharmaceutical Technology →
GSK says it is balancing West and East in licensing strategy
A GSK executive said the company has pursued a strategy of “balancing the West and the East” over the past two years in licensing drug candidates, citing the success of its Hansoh deal.
Fierce Biotech →$GSK
Business & Finance
Trump administration removes about 760,000 Obamacare enrollments
The White House Task Force to Eliminate Fraud, led by Vice President JD Vance, removed roughly 760,000 Obamacare enrollments over alleged fraud, and estimates the action will save about $2.2 billion in taxpayer-funded subsidies.
CNBC →
Parties dispute intent standard in Stelara antitrust appeal
In CareFirst’s antitrust case over Stelara (ustekinumab), the U.S. District Court for the Eastern District of Virginia reconsidered its December 2025 summary judgment decision on January 14, 2026 and granted summary judgment to Johnson & Johnson and Janssen Biotech; the parties now dispute the applicable intent standard on appeal.
Big Molecule Watch →$JNJ
AstraZeneca extends UNICEF youth health programme past $100M
AstraZeneca renewed its UNICEF-partnered Young Health Programme for a new five-year phase, taking total investment in the initiative above $100 million.
Fierce Pharma →$AZN
UK’s NIHR opens £45M funding call for research partnerships
The UK’s National Institute for Health and Care Research announced a first £45 million funding call for projects addressing the translation gap in healthcare, with an initial focus on community care.
Pharmaphorum →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.